The estimated Net Worth of Martin Charles Faulkes is at least $1.68 millió dollars as of 31 August 2023. Martin Faulkes owns over 9,716 units of VolitionRX Ltd stock worth over $1,169,799 and over the last 10 years he sold VNRX stock worth over $208,650. In addition, he makes $298,832 as Executive Chairman of the Board at VolitionRX Ltd.
Martin has made over 11 trades of the VolitionRX Ltd stock since 2014, according to the Form 4 filled with the SEC. Most recently he bought 9,716 units of VNRX stock worth $12,436 on 31 August 2023.
The largest trade he's ever made was buying 79,269 units of VolitionRX Ltd stock on 11 June 2019 worth over $246,527. On average, Martin trades about 10,914 units every 86 days since 2014. As of 31 August 2023 he still owns at least 1,673,532 units of VolitionRX Ltd stock.
You can see the complete history of Martin Faulkes stock trades at the bottom of the page.
Dr. Martin Charles Faulkes serves as Executive Chairman of the Board of the Company. Prior to completion of the transactions under the Share Exchange Agreement, Dr. Faulkes served as a Director of Singapore Volition from August 18, 2010 to December 15, 2015 and as Executive Chairman of the board of directors of Singapore Volition from March 22, 2011 until December 15, 2015. Dr. Faulkes also served as a Director of Belgian Volition between August 10, 2011 and March 31, 2016. On August 7, 2019, Dr. Faulkes was appointed a Manager and President of Volition Vet. From 1998 until the present day, Dr. Faulkes has focused on charitable activities, as the founder and sole benefactor of The Dill Faulkes Educational Trust, a U.K. registered charity, where he is Chairman. He also sits on the board of the Cambridge 800th Anniversary Campaign in the U.K. Prior to Dr. Faulkes’ charitable activities he founded Triad Plc., a computer software development company that provides systems and consultants to the business community, where he was a Director from 1987 to 1998, and responsible for controlling the company financially. From 1985 to 1987, he became Managing Director of System Programming Ltd., a company that provides computer programming for systems in businesses such as airlines, utility companies, banks, and insurance companies, where he was responsible for all aspects of the business. Prior to System Programming Ltd., Dr. Faulkes served from 1979 to 1984 as founder, President and Chief Executive Officer for Logica Inc., a company providing bespoke software to all industries but mainly banks and communications companies. Dr. Faulkes was responsible for all aspects of the business, including sales, finance, recruitment, staff management and project control. Dr. Faulkes has over 40 years of entrepreneurial and managerial experience as the founder and Chief Executive Officer of several software companies within the United Kingdom and the United States. Our board of directors believes that Dr. Faulkes is qualified to serve as a
As the Executive Chairman of the Board of VolitionRX Ltd, the total compensation of Martin Faulkes at VolitionRX Ltd is $298,832. There are 5 executives at VolitionRX Ltd getting paid more, with Cameron Reynolds having the highest compensation of $517,691.
Martin Faulkes is 75, he's been the Executive Chairman of the Board of VolitionRX Ltd since 2013. There are 1 older and 20 younger executives at VolitionRX Ltd. The oldest executive at VolitionRX Ltd is Dr. Martin Charles Faulkes Ph.D., 77, who is the Exec. Chairman.
Martin's mailing address filed with the SEC is 1489 WEST WARM SPRINGS ROAD, SUITE 110, HENDERSON, NV, 89014.
Over the last 12 years, insiders at VolitionRX Ltd have traded over $775,239 worth of VolitionRX Ltd stock and bought 1,908,474 units worth $44,487,770,972 . The most active insiders traders include Guy Archibald Innes, Cameron John Reynolds és Martin Charles Faulkes. On average, VolitionRX Ltd executives and independent directors trade stock every 43 days with the average trade being worth of $27,899. The most recent stock trade was executed by Guy Archibald Innes on 20 August 2024, trading 150,000 units of VNRX stock currently worth $100,500.
volitionrx is a life sciences company whose goal is to make its non-invasive blood tests for cancer as common and simple to use as existing diabetic and cholesterol tests on similar formats. volitionrx’s development activities are currently centered in belgium with a focus on bringing its revolutionary diagnostic products to market first in europe, then the u.s. and worldwide. you can find more information about volitionrx at our website at www.volitionrx.com, on twitter at www.twitter.com/volitionrx, linkedin at http://www.linkedin.com/company/volitionrx or facebook at www.facebook.com/volitionrx.
VolitionRX Ltd executives and other stock owners filed with the SEC include: